Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgical complications and risk factors in elderly patients after kidney transplantation: A single-center retrospective study.

The French journal of urology·2026
Same author

Small extracellular vesicle-mediated transfer of HPV16 transcripts from Ca Ski cells increases proliferation of HPV-negative recipient cancer cells.

Cell communication and signaling : CCS·2026
Same author

Corrigendum to "Combination of CDX2H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer" [In European Journal of Cancer, Volume 172, 2022, Pages 221-230, ISSN 0959-8049].

European journal of cancer (Oxford, England : 1990)·2026
Same author

Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm: assessing spatial response and unraveling resistance mechanisms.

Haematologica·2026
Same author

Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective Study.

European urology oncology·2026
Same author

Dynamic DNA methylation changes during colorectal oncogenesis with insights from adenoma stages.

Scientific reports·2025

Related Experiment Video

Updated: Jul 11, 2026

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

14.7K

Concomitant decrease of E- and A-FABP expression predicts worse survival in urothelial bladder cancer patients.

Inès Saizonou1, Isabelle Lascombe2, Franck Monnien1

  • 1CHU Besançon, Service Anatomie et Cytologie Pathologiques, 25000, Besançon, France.

Scientific Reports
|July 4, 2024
PubMed
Summary

Assessing Epidermal-Fatty Acid Binding Protein (E-FABP) in non-muscle invasive bladder cancer (NMIBC) reveals its prognostic value. Combined with Adipocyte-Fatty Acid Binding Protein (A-FABP) evaluation, E-FABP aids in stratifying urothelial carcinoma patients for tailored treatment and follow-up.

More Related Videos

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:25

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

1.8K
Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
04:57

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

460

Related Experiment Videos

Last Updated: Jul 11, 2026

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

14.7K
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:25

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

1.8K
Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
04:57

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

460

Area of Science:

  • Oncology
  • Molecular Pathology
  • Urothelial Carcinoma Research

Background:

  • Non-muscle invasive bladder cancers (NMIBC) present unpredictable clinical courses with high recurrence and progression risks.
  • Previous research indicated Adipocyte-Fatty Acid Binding Protein (A-FABP) loss as a predictor of NMIBC progression.
  • Identifying reliable biomarkers for NMIBC progression is crucial for patient management.

Purpose of the Study:

  • To investigate the prognostic significance of Epidermal-Fatty Acid Binding Protein (E-FABP) expression in NMIBC.
  • To explore the combined prognostic value of E-FABP and A-FABP in urothelial carcinoma.
  • To stratify patients for optimized treatment and follow-up strategies.

Main Methods:

  • Immunohistochemistry was employed to assess E-FABP expression in 210 NMIBC tumor specimens (pTa-pT1).
  • Correlation analysis was performed to link E-FABP expression with tumor grade, stage, lymph node metastasis, and visceral metastases.
  • Kaplan-Meier analysis was used to evaluate the association of E-FABP expression with recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS).

Main Results:

  • Low E-FABP expression correlated significantly with high grade/stage, lymph node metastases, and visceral metastases (p < 0.001).
  • While low E-FABP expression did not predict RFS or PFS, high E-FABP expression was associated with longer overall survival (53.8 months vs. 29.3 months, p = 0.029).
  • A compensatory relationship was observed: high E-FABP expression was detected when A-FABP was absent. Patients with both low E-FABP and negative A-FABP showed the worst survival, whereas those expressing both markers had better survival.

Conclusions:

  • Combined evaluation of A-FABP and E-FABP expression provides a robust method for stratifying urothelial carcinoma patients.
  • This combined biomarker approach can aid in optimizing treatment decisions and follow-up protocols for NMIBC.
  • E-FABP serves as a potential prognostic marker, particularly when assessed alongside A-FABP, for managing bladder cancer patients.